Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Cash & Current Investments (2016 - 2026)

Oramed Pharmaceuticals filings provide 16 years of Cash & Current Investments readings, the most recent being $51.4 million for Q4 2025.

  • Quarterly Cash & Current Investments fell 11.23% to $51.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $51.4 million through Dec 2025, down 11.23% year-over-year, with the annual reading at $51.4 million for FY2025, 11.23% down from the prior year.
  • Cash & Current Investments hit $51.4 million in Q4 2025 for Oramed Pharmaceuticals, down from $57.1 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $154.3 million in Q3 2022 and bottomed at $23.3 million in Q2 2025.
  • Average Cash & Current Investments over 5 years is $76.3 million, with a median of $64.6 million recorded in 2021.
  • The largest annual shift saw Cash & Current Investments skyrocketed 413.7% in 2021 before it crashed 73.07% in 2025.
  • Oramed Pharmaceuticals' Cash & Current Investments stood at $39.5 million in 2021, then increased by 12.05% to $44.2 million in 2022, then surged by 51.03% to $66.8 million in 2023, then fell by 13.34% to $57.9 million in 2024, then decreased by 11.23% to $51.4 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Cash & Current Investments are $51.4 million (Q4 2025), $57.1 million (Q3 2025), and $23.3 million (Q2 2025).